Allspring Global Investments Holdings LLC lifted its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 46.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,724 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,182 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Collegium Pharmaceutical were worth $80,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also recently modified their holdings of the company. Altshuler Shaham Ltd bought a new stake in Collegium Pharmaceutical in the 4th quarter worth about $28,000. Captrust Financial Advisors grew its stake in shares of Collegium Pharmaceutical by 97.5% during the 1st quarter. Captrust Financial Advisors now owns 2,151 shares of the specialty pharmaceutical company’s stock valued at $44,000 after purchasing an additional 1,062 shares during the period. PNC Financial Services Group Inc. grew its stake in shares of Collegium Pharmaceutical by 233.9% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,224 shares of the specialty pharmaceutical company’s stock valued at $44,000 after purchasing an additional 1,558 shares during the period. WealthPlan Investment Management LLC bought a new stake in shares of Collegium Pharmaceutical during the 1st quarter valued at about $45,000. Finally, UBS Group AG grew its stake in shares of Collegium Pharmaceutical by 300.0% during the 3rd quarter. UBS Group AG now owns 3,556 shares of the specialty pharmaceutical company’s stock valued at $57,000 after purchasing an additional 2,667 shares during the period.
Analyst Upgrades and Downgrades
A number of research analysts recently issued reports on COLL shares. Needham & Company LLC boosted their price objective on Collegium Pharmaceutical from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Friday, August 25th. StockNews.com upgraded Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. Finally, HC Wainwright reiterated a “neutral” rating on shares of Collegium Pharmaceutical in a research note on Friday, August 4th.
Collegium Pharmaceutical Stock Up 0.6 %
Shares of COLL opened at $25.12 on Friday. The stock has a market capitalization of $819.16 million, a price-to-earnings ratio of 167.47 and a beta of 0.91. Collegium Pharmaceutical, Inc. has a 1 year low of $20.80 and a 1 year high of $30.22. The business’s 50 day simple moving average is $22.72 and its 200-day simple moving average is $22.69. The company has a debt-to-equity ratio of 2.95, a current ratio of 1.16 and a quick ratio of 1.08.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
- Five stocks we like better than Collegium Pharmaceutical
- How to Invest in Blockchain Stocks Step by Step
- Amazon, Target, Walmart in a race for fastest delivery
- What are stock market earnings reports?
- Palo Alto Networks: the one security stock to rule them all
- How to Invest in Semiconductors
- Is it time to buy the dip in Walmart shares?
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.